Glenmark Pharmaceuticals

Mumbai, India Founded: 1977 • Age: 49 yrs Listed Fortune India 500 · #201
RD company focused on manufacturing generic drugs for multiple therapeutic areas
Request Access
Report Incorrect Data
Page last updated

About Glenmark Pharmaceuticals

Glenmark Pharmaceuticals is a publicly listed company based in Mumbai (India) founded in 1977. RD company focused on manufacturing generic drugs for multiple therapeutic areas. The company has 13,648 employees. Its website glenmarkpharma.com draws about 106 thousand monthly visits. Its Indian entity Glenmark Pharmaceuticals Limited reported revenue of ₹17,443 Cr. Glenmark Pharmaceuticals offers products and services including Pharmaceutical Formulations and Therapy Areas Products. Its focus areas include Diversified Pharmaceuticals and Drugs.

Company details

Glenmark Pharmaceuticals was founded in 1977 and is headquartered in Mumbai, India. Operations are centered on research and development, with a focus on manufacturing generic drugs across various therapeutic areas. The company serves global markets by producing affordable medications for conditions including dermatology, respiratory, and cardiovascular disorders. Leadership is provided by Managing Director Glenn Saldanha, overseeing strategic initiatives in the pharmaceutical sector.

Glenmark Pharmaceuticals is ranked #201 on the Fortune India 500 (2025).

Recognitions & Rankings of Glenmark Pharmaceuticals

Fortune India 500 2025 edition
Rank#201
Total income
₹13,649 Cr
Profit
₹1,047 Cr
Last year #188
India's Most Valuable Companies 2024 edition · Source: Hurun India
Rank#144
Valuation
₹42,720 Cr
2023 #206 2022 #298 2021 #253
Operational Areas
Healthcare → Pharmaceuticals & Distribution
Key Metrics
  • Market Cap
    ₹75,385 Cr

    GLENMARK · NSE

  • Share Price
    ₹2,677.20

    +0.23% today

  • Revenue
    ₹16,983 Cr

    FY 2025-26 · +27.5% YoY

  • EBITDA
    ₹2,306 Cr

    Margin 13.6%

  • Net Profit
    ₹2,281 Cr

    FY 2025-26 · +73.0% YoY

  • P/E (TTM)
    36.2x

    P/B 6.5x

  • ROE
    23.6%

    ROCE 35.1%

  • Debt / Equity
    0.16

    Interest cover 12.1x

  • Latest Funding Round
    $200M (USD), Debt – Conventional

    Sep 2019

  • Employee Count
    13,648

Products & Services of Glenmark Pharmaceuticals

Glenmark Pharmaceuticals offers a comprehensive portfolio of products and services, including Pharmaceutical Formulations and Therapy Areas Products.

Pharmaceutical Formulations
Drug Manufacturing

Develops and produces formulations for therapy areas like oncology

Therapy Areas Products
Specialty Drugs

Focuses on innovative therapies in dermatology and respiratory

Funding Insights of Glenmark Pharmaceuticals

  • Total Rounds 1
  • Last Round Debt – Conventional — $200M
  • First Round $200M

    (Sep 2019)

All 1 funding rounds of Glenmark Pharmaceuticals with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.

DateAmountTransaction NameValuationLead InvestorsInvestors
Sep 2019$200MDebt – Conventional––
–

Board of directors of Glenmark Pharmaceuticals Limited (Glenmark Pharmaceuticals)

Glenmark Pharmaceuticals Limited is the primary company behind Glenmark Pharmaceuticals. The board of Glenmark Pharmaceuticals Limited currently have 9 directors; the longest-serving is Glenn Mario Saldanha, appointed in 1998. 19 earlier directors have ceased.

DirectorDesignationAppointedTenureEntity
Glenn Mario Saldanha
DIN 00050607
Managing Director12 Oct 199828 yrsGlenmark Pharmaceuticals Limited
Cherylann Maria Pinto
DIN 00111844
Whole-time director16 May 200719 yrs 5 moGlenmark Pharmaceuticals Limited
Blanche Saldanha Elizabeth
DIN 00007671
Director14 Aug 200917 yrs 2 moGlenmark Pharmaceuticals Limited
Sona Saira Ramasastry
DIN 08398547
Director01 Apr 20197 yrs 7 moGlenmark Pharmaceuticals Limited
Dipankar Bhattacharjee
DIN 08770548
Director14 Aug 20206 yrs 2 moGlenmark Pharmaceuticals Limited
Vijayalakshmi Iyer
DIN 05242960
Director10 Feb 20233 yrs 9 moGlenmark Pharmaceuticals Limited
Pradeep Kumar Sinha
DIN 00145126
Director14 Feb 20251 yr 8 moGlenmark Pharmaceuticals Limited
Anurag Mantri
DIN 05326463
Whole-time director27 May 20251 yr 5 moGlenmark Pharmaceuticals Limited
Patricia Susan Andrews
DIN 11211749
Director14 Aug 20251 yr 2 moGlenmark Pharmaceuticals Limited

People of Glenmark Pharmaceuticals

18 people are tracked at Glenmark Pharmaceuticals (7 in leadership, 10 in board & advisors, 1 in team); the tracked headcount is 13,648.

NameRoleGroup
Glenn Saldanha
Managing DirectorLeadership
Sriram Venkatasubramanian
President & Head, Global Operations & Supply ChainLeadership
Alind Sharma
President & Global CHROLeadership
Ulhas Dhuppad
President & Head, Global Pharmaceutical DevelopmentLeadership
Brendan Ogrady
CEO, Global Formulations BusinessLeadership
Nikhil Amin
President, Innovative Medicines Group & Chief Scientific OfficerLeadership
V. S. Mani
Executive Director & Global CFOLeadership
Rajesh V. Desai
DirectorBoard & advisors
Brian W. Tempest
DirectorBoard & advisors
Saira Ramasastry
DirectorBoard & advisors
Blanche E. Saldanha
DirectorBoard & advisors
Sridhar Gorthi
DirectorBoard & advisors
Dipankar Bhattacharjee
DirectorBoard & advisors
D. R. Mehta
DirectorrBoard & advisors
Cherylann Pinto
DirectorBoard & advisors
Bernard Munos
DirectorBoard & advisors
Vijayalakshmi Rajaram Iyer
Non-Executive Independent DirectorBoard & advisors
Lucy V
HrTeam
Premium access

Complete people profiles for Glenmark Pharmaceuticals

Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.

  • Full employee list
  • Team structure
  • Board tenure
  • Professional contacts

Verified entity values are shown only after access is granted.

IPO & Listings of Glenmark Pharmaceuticals

Glenmark Pharmaceuticals is a publicly listed company on the NSE with ticker symbol GLENMARK in India, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.

  • IPO date10 Feb 2000
  • Listed onBSE: 532296
  • Listed entityGlenmark Pharmaceuticals Limited
  • Exchange sectorHealth technology
  • ISININE935A01035
  • Share price₹2,246.00 (-0.85% on the day) · 2026-10-14
  • Market capitalisation₹63,980 Cr
  • Price to earnings35.3
  • EPS (diluted, trailing year)₹63.69
  • Dividend yield0.22%
  • Volume (last session)257,936

Financials of Glenmark Pharmaceuticals

Exchange-reported figures of Glenmark Pharmaceuticals Limited, the listed company behind Glenmark Pharmaceuticals (NSE: GLENMARK).

Financial Highlights

FY 2025-26 · Consolidated
Revenue
₹16,983 Cr
+27.5% YoY
EBITDA
₹2,306 Cr
+16.6% YoY
Profit After Tax
₹2,281 Cr
+73.0% YoY
Net Worth
₹10,512 Cr
+18.8% YoY
Total Assets
₹13,637 Cr
+15.6% YoY
Total Debt
₹594 Cr
-76.0% YoY

Revenue vs Net Profit ₹ Cr

Margin trends

Financial summary ₹ Cr

MetricsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Income statement
Revenue16,98313,32211,81311,58312,30510,94410,641
Revenue growth+27.5%+12.8%+2.0%-5.9%+12.4%+2.9%-
EBITDA2,3061,9792948692,0592,0841,698
EBITDA margin+13.6%+14.9%+2.5%+7.5%+16.7%+19.1%+16.0%
Profit before tax1,9851,3994347071,4411,3821,096
Net profit2,2811,318(4,474)6101,108941756
Net profit margin+13.4%+9.9%-37.9%+5.3%+9.0%+8.6%+7.1%
EPS (₹)48.2637.11(53.21)10.5333.3734.3827.50
Balance sheet
Total assets13,63711,7989,61914,84513,55312,24711,368
Net worth10,5128,8497,8489,4749,0877,0656,071
Total debt5942,4731,2314,6083,9624,9864,869
Cash & bank1,1761,7051,6591,1601,4121,1391,111
Net working capital5,0305,1022,6896,1994,7834,0313,503
Cash flow
Cash from operations3,445(828)(265)6251,1091,1311,392
Cash from investing(1,237)57.994,387(515)(316)(662)(774)
Cash from financing(2,709)787(3,906)(77.46)(520)(442)(445)
ParticularsSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024
Revenue4,2474,0183,7713,9016,0473,2643,2563,388
Revenue growth (YoY)-29.8%+23.1%+15.8%+15.2%+76.1%+0.6%--
Other income2.5465.7618944.4720126.4411.6931.13
EBITDA580805389685974257188600
EBITDA margin+14.0%+20.5%+10.4%+17.6%+16.2%+8.4%+5.8%+18.2%
Depreciation180173148154141130125123
Interest63.7754.0042.6041.4366.4658.2366.7152.29
Profit before tax33864338853496795.577.97456
Tax74.4516186.4513135748.603.59108
Net profit26448330140361046.974.38348
EPS (₹)9.3417.1110.6814.2821.621.660.1612.33
MetricsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Income statement
Revenue8,4409,2267,8918,2218,1427,5686,713
Revenue growth-8.5%+16.9%-4.0%+1.0%+7.6%+12.7%-
EBITDA(723)2,0651,2429771,6881,8901,304
EBITDA margin-8.6%+22.4%+15.7%+11.9%+20.7%+25.0%+19.4%
Profit before tax(266)2,1547,0011,5722,3371,9441,535
Net profit9421,7631,4251,5781,6441,5901,340
Net profit margin+11.2%+19.1%+18.1%+19.2%+20.2%+21.0%+20.0%
EPS (₹)(7.12)57.07183.1142.8470.8058.4648.00
Balance sheet
Total assets25,84825,46623,81021,47120,59818,65017,006
Net worth24,15024,50422,97117,87716,73914,81013,226
Total debt1078307073,2213,7383,7043,574
Cash & bank29313312993.7929.6315.7988.26
Net working capital2,4582,2681,0771,2712,0862,9422,478
Cash flow
Cash from operations543589(495)1,4741,2161,2431,579
Cash from investing569(490)3,197(432)(897)(1,235)(1,607)
Cash from financing(952)(95.41)(2,666)(978)(305)(80.79)(139)
ParticularsSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024
Revenue2,4762,4352,1472,3601,5392,3952,0102,251
Revenue growth (YoY)+60.9%+1.7%+6.8%+4.8%-41.6%+2.8%--
Other income10833830810928669.3488.45129
Total expenses1,9371,8222,4842,0412,6481,9901,8481,757
EBITDA539613(337)319(1,110)405161494
EBITDA margin+22.7%+26.2%-15.3%+13.7%-91.0%+18.6%+8.4%+22.4%
Depreciation63.0062.3260.1359.1858.9357.6455.5355.16
Interest30.9323.2517.9121.9823.4015.4613.138.46
Profit before tax553866(107)347(906)401181560
Tax118130(33.50)64.46(167)70.9433.40146

Financial Statements

Figures in ₹ Cr; negatives in brackets. Updated 11 Nov 2026
ParticularsSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024
Revenue4,2474,0183,7713,9016,0473,2643,2563,388
Revenue growth (YoY)-29.8%+23.1%+15.8%+15.2%+76.1%+0.6%--
Other income2.5465.7618944.4720126.4411.6931.13
EBITDA580805389685974257188600
EBITDA margin+14.0%+20.5%+10.4%+17.6%+16.2%+8.4%+5.8%+18.2%
Depreciation180173148154141130125123
Interest63.7754.0042.6041.4366.4658.2366.7152.29
Profit before tax33864338853496795.577.97456
Tax74.4516186.4513135748.603.59108
Net profit26448330140361046.974.38348
EPS (₹)9.3417.1110.6814.2821.621.660.1612.33
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Revenue16,98313,32211,81311,58312,30510,94410,641
Revenue growth+27.5%+12.8%+2.0%-5.9%+12.4%+2.9%-
Other income4611141,23775616794.76192
Total expenses14,67611,34311,51910,71410,2468,8608,943
Employee cost3,5783,0222,8682,6012,4472,3442,255
EBITDA2,3061,9792948692,0592,0841,698
EBITDA margin+13.6%+14.9%+2.5%+7.5%+16.7%+19.1%+16.0%
Depreciation573486582569487444417
Interest209207516349298353377
Profit before tax1,9851,3994347071,4411,3821,096
Tax6233521,867329448412320
Net profit2,2811,318(4,474)6101,108941756
Net profit margin+13.4%+9.9%-37.9%+5.3%+9.0%+8.6%+7.1%
EPS (₹)48.2637.11(53.21)10.5333.3734.3827.50
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Equity & liabilities
Share capital28.2228.2228.2228.2228.2228.2228.22
Reserves & surplus10,4848,8217,8209,4469,0587,0366,042
Shareholders' funds (net worth)10,5128,8497,8489,4749,0877,0656,071
Minority interest(0.32)(0.37)(0.38)365351(0.35)(0.39)
Secured loans0.002991570.000.000.000.00
Unsecured loans5942,1741,0744,6083,9624,9864,869
Total debt5942,4731,2314,6083,9624,9864,869
Total liabilities13,63711,7989,61914,84513,55312,24711,368
Assets
Gross block12,07210,3659,62010,36010,2138,7328,270
Net block5,9154,4874,2105,4225,8875,1295,029
Capital work in progress9098356621,1901,0101,3821,222
Investments42.3656.3679044.5749.6224.6324.59
Inventories3,4313,0292,5132,3742,5002,2772,136
Sundry debtors4,9633,3421,8583,6653,1012,5722,409
Cash & bank balances1,1761,7051,6591,1601,4121,1391,111
Loans & advances1,7291,2201,3973,5261,2701,3721,148
Total current assets11,3009,2957,42810,7268,2827,3606,804
Total current liabilities6,2694,1934,7394,5263,4993,3283,300
Net working capital5,0305,1022,6896,1994,7834,0313,503
Total assets13,63711,7989,61914,84513,55312,24711,368
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Opening cash1,6761,6581,4431,4111,1381,110936
Net cash from operating activities3,445(828)(265)6251,1091,1311,392
Net cash from investing activities(1,237)57.994,387(515)(316)(662)(774)
Net cash from financing activities(2,709)787(3,906)(77.46)(520)(442)(445)
Net change in cash(501)17.4421532.5027227.82174
Closing cash1,1761,7051,6591,1601,4121,1391,111
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Growth
Sales growth+27.5%+12.8%+2.0%-5.9%+12.4%+2.9%-
EBITDA growth+16.6%+572.1%-66.1%-57.8%-1.2%+22.8%-
PBT growth+41.9%+222.5%-38.6%-51.0%+4.3%+26.1%-15.7%
Net income growth+73.0%+129.5%-833.8%-45.0%+17.7%+24.6%-
Revenue CAGR (3Y)+13.6%+2.7%+2.6%+2.9%+7.6%+6.4%+5.4%
EBITDA CAGR (3Y)+38.4%-1.3%-47.9%-20.0%+9.1%+8.9%-4.6%
Profitability & leverage
Net income margin+8.0%+7.9%-12.1%+3.3%+8.1%+8.9%+7.3%
Return on capital employed+35.1%+18.5%+12.1%+9.8%+15.8%+14.7%+13.7%
Return on net worth+23.6%+15.8%-50.9%+7.4%+14.4%+14.8%+13.3%
Debt / equity0.160.220.340.460.550.750.80
Long-term debt / equity0.060.050.240.370.430.620.65
Interest cover12.0513.87-179.45116.3518.9621.5229.46
Efficiency & per share
Fixed asset turnover1.511.331.181.131.301.291.44
Inventory turnover5.264.814.834.755.154.964.85
Debtors turnover4.095.124.283.424.344.394.62
EPS (₹)48.2637.11(53.21)10.5333.3734.3827.50
Dividend per share (₹)5.002.502.502.502.502.502.50
Book value per share (₹)372.51313.60278.11335.75322.03250.37215.14
ParticularsSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024
Revenue2,4762,4352,1472,3601,5392,3952,0102,251
Revenue growth (YoY)+60.9%+1.7%+6.8%+4.8%-41.6%+2.8%--
Other income10833830810928669.3488.45129
Total expenses1,9371,8222,4842,0412,6481,9901,8481,757
EBITDA539613(337)319(1,110)405161494
EBITDA margin+22.7%+26.2%-15.3%+13.7%-91.0%+18.6%+8.4%+22.4%
Depreciation63.0062.3260.1359.1858.9357.6455.5355.16
Interest30.9323.2517.9121.9823.4015.4613.138.46
Profit before tax553866(107)347(906)401181560
Tax118130(33.50)64.46(167)70.9433.40146
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Revenue8,4409,2267,8918,2218,1427,5686,713
Revenue growth-8.5%+16.9%-4.0%+1.0%+7.6%+12.7%-
Other income7723566,2389861,045470625
Total expenses9,1647,1616,6497,2446,4535,6785,408
Employee cost1,7901,6041,4351,3471,1931,1071,072
EBITDA(723)2,0651,2429771,6881,8901,304
EBITDA margin-8.6%+22.4%+15.7%+11.9%+20.7%+25.0%+19.4%
Depreciation236219202184160151139
Interest78.7548.73277207236266256
Profit before tax(266)2,1547,0011,5722,3371,9441,535
Tax(65.27)5441,833363340294180
Net profit9421,7631,4251,5781,6441,5901,340
Net profit margin+11.2%+19.1%+18.1%+19.2%+20.2%+21.0%+20.0%
EPS (₹)(7.12)57.07183.1142.8470.8058.4648.00
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Equity & liabilities
Share capital28.2228.2228.2228.2228.2228.2228.22
Reserves & surplus24,12224,47622,94217,84916,71014,78113,198
Shareholders' funds (net worth)24,15024,50422,97117,87716,73914,81013,226
Secured loans0.002990.000.000.000.000.00
Unsecured loans1075317073,2213,7383,7043,574
Total debt1078307073,2213,7383,7043,574
Total liabilities25,84825,46623,81021,47120,59818,65017,006
Assets
Gross block4,0163,7433,3933,1843,0262,8492,595
Net block2,0281,9791,7561,7461,7521,7221,612
Capital work in progress159155198172109131200
Investments15,20215,19512,96510,3348,5596,9904,714
Inventories1,2881,3691,1431,090952762838
Sundry debtors3,3062,5502,4842,5062,6782,4891,835
Cash & bank balances29313312993.7929.6315.7988.26
Loans & advances1,2087259256967431,6421,663
Total current assets6,0954,7784,6814,3854,4034,9094,424
Total current liabilities3,6372,5093,6053,1152,3171,9671,946
Net working capital2,4582,2681,0771,2712,0862,9422,478
Total assets25,84825,46623,81021,47120,59818,65017,006
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Opening cash13112892.7028.6514.7287.29255
Net cash from operating activities543589(495)1,4741,2161,2431,579
Net cash from investing activities569(490)3,197(432)(897)(1,235)(1,607)
Net cash from financing activities(952)(95.41)(2,666)(978)(305)(80.79)(139)
Net change in cash1603.4935.2764.0513.93(72.57)(168)
Closing cash29313312993.7929.6315.7988.26
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Growth
Sales growth-8.5%+16.9%-4.0%+1.0%+7.6%+12.7%-
EBITDA growth-135.0%+66.3%+27.1%-42.1%-10.7%+44.9%-
PBT growth--69.2%+345.4%-32.8%+20.3%+26.7%-21.4%
Net income growth-46.6%+23.7%-9.7%-4.0%+3.4%+18.6%-
Revenue CAGR (3Y)+0.9%+4.3%+1.4%+7.0%+8.9%+11.1%-5.6%
EBITDA CAGR (3Y)-+7.0%-13.1%-9.2%+8.3%+19.7%-21.2%
Profitability & leverage
Net income margin-2.4%+17.5%+65.5%+14.7%+24.5%+21.8%+20.2%
Return on capital employed+6.3%+8.9%+9.8%+10.8%+10.9%+12.4%+11.1%
Return on net worth+3.9%+6.8%+7.0%+9.1%+10.4%+11.8%+10.8%
Debt / equity0.020.030.100.200.240.260.27
Long-term debt / equity0.000.000.070.150.180.220.24
Interest cover-8.212.6426.6626.0915.4415.2921.99
Efficiency & per share
Fixed asset turnover2.182.592.402.652.772.782.77
Inventory turnover6.357.357.078.059.509.467.68
Debtors turnover2.883.673.163.173.153.503.42
EPS (₹)(7.12)57.07183.1142.8470.8058.4648.00
Dividend per share (₹)5.002.502.502.502.502.502.50
Book value per share (₹)855.79868.35814.01633.57593.21524.84468.73

Timeline of Glenmark Pharmaceuticals

3 dated milestones of Glenmark Pharmaceuticals across 42 years, from founding to its latest funding, stage changes and deals.

  1. Founded Glenmark Pharmaceuticals is founded.
  2. IPO Lists on the stock exchange (IPO).
  3. Funding First funding round of $200.0M.

Web traffic of Glenmark Pharmaceuticals

The website of Glenmark Pharmaceuticals (glenmarkpharma.com) receives about 106.3K visits a month.

  • Monthly visits
    106.3K

    ▲ 63.3% vs previous month

Similar websites

Websites whose visitors overlap most with Glenmark Pharmaceuticals. Affinity shows how closely the audiences match.

WebsiteDomainAudience affinityMonthly visitsGlobal rankProfile
Torrent Pharma
torrentpharma.com
100%
31.6K#932,209View details
GSK
gsk.com
88%
1.3M#56,834View details
Ranbaxy Laboratories
ranbaxy.com
82%
View details
Dr. Reddy's Laboratories
drreddys.com
80%
118.8K#308,607View details
alembic-india.com
alembic-india.com
80%
–
••••••••••••••••.com••%•.•M#•••••–
••••••••••••••••.com••%•.•M#•••••–
••••••••••••••••.com••%•.•M#•••••–
Premium access

All 40 similar websites and full traffic analytics for Glenmark Pharmaceuticals

The complete similar-websites list, audience overlap and engagement analytics require an active premium plan.

  • 40 similar websites
  • Audience overlap
  • Engagement analytics
  • Traffic by brand

Verified entity values are shown only after access is granted.

Upgrade to premium

Unlock complete access to The Company Check

Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.

Upgrade to Premium No viewing limits. Your plan controls exports and screening usage.
Included in your Premium account
  • ✓
    Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
  • ✓
    Full access to every database India & global coverage, advanced filters and rich profile details
  • ✓
    Always-on access from your team account Single premium plan for everything you see on the portal

Related news about Glenmark Pharmaceuticals

Glenmark Pharma: Expects Consistent 15-20% Growth In Emerging Markets, Plans To Generate $30 Million To $40 Million From Partnered Innovative Oncology Drugs By FY28
Exchange Update • 5 days ago
Glenmark Pharma: Confirms That Increased Efficiency Will Fully Eliminate Gross Debt By FY27, Improving Financial Flexibility.
Exchange Update • 5 days ago
Glenmark: Bulk Of Legal Issues Resolved In The U.S., Easing Pressure On The Company.
Exchange Update • 5 days ago
GLENMARK: Q2 EBITDA 8.64B RUPEES VS 23.6B (YOY); Q2 EBITDA MARGIN 20.34% VS 39.02% (YOY)
Exchange Update • 6 days ago
GLENMARK: Q2 REVENUE 42.47B RUPEES VS 60.47B (YOY)
Exchange Update • 6 days ago
GLENMARK: Q2 CONS NET PROFIT 2.64B RUPEES VS 6.1B (YOY)
Exchange Update • 6 days ago
Glenmark Pharma arm launches Adapalene Gel USP in new pump packs, targeting a market valued at $45.8 million
Udaipur Kiran • 1 month ago
Glenmark: Glenmark Therapeutics Inc., USA Introduces Pump Packs for Adapalene Gel USP With Annual Sales Around USD 45.8 Million
Exchange Update • 1 month ago
Glenmark Pharma receives US FDA EIR for Goa plant; inspection closed with VAI status
Moneycontrol • 1 month ago
Glenmark Pharma: Gets EIR From U.S. FDA For Goa Facility With VAI Status
Exchange Update • 1 month ago
Premium access

Complete news archive for Glenmark Pharmaceuticals

Full article history, source details, and older brand coverage require an active premium plan.

  • Full article archive
  • Source and publication date
  • Older coverage
  • Brand-specific news history

Verified entity values are shown only after access is granted.

Articles about Glenmark Pharmaceuticals on our blog

Frequently Asked Questions about Glenmark Pharmaceuticals

Glenmark Pharmaceuticals was founded in 1977 and raised its 1st funding round 42 years after it was founded.

Glenmark Pharmaceuticals is headquartered in Mumbai, India. It is registered at Mumbai, Maharashtra, India.

Glenmark Pharmaceuticals has 13,648 employees.

The primary company behind Glenmark Pharmaceuticals, Glenmark Pharmaceuticals Limited, reported revenue of ₹17,443 Cr for FY 2026, up 27% year on year.

Glenmark Pharmaceuticals was founded in 1977 and is headquartered in Mumbai, India. Operations are centered on research and development, with a focus on manufacturing generic drugs across various therapeutic areas. The company serves global markets by producing affordable medications for conditions including dermatology, respiratory, and cardiovascular disorders. Leadership is provided by Managing Director Glenn Saldanha, overseeing strategic initiatives in the pharmaceutical sector.

Glenmark Pharmaceuticals offers Pharmaceutical Formulations and Therapy Areas Products.

Yes, Glenmark Pharmaceuticals is publicly traded on NSE under the ticker symbol GLENMARK.

Glenmark Pharmaceuticals operates through Glenmark Pharmaceuticals Limited.

The legal entities of Glenmark Pharmaceuticals currently have 10 directors, including Sona Saira Ramasastry, Glenn Mario Saldanha, Blanche Saldanha Elizabeth and others.

The website of Glenmark Pharmaceuticals receives about 106 thousand visits a month.

Explore millions of companies — effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals — all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available